No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RDNT240719P60000
- 1.35
- -2.65-66.25%
15min DelayClose Jul 11 15:59 ET
2.45High1.30Low
1.70Open4.00Pre Close123 Volume526 Open Interest60.00Strike Price20.18KTurnover34.02%IV1.99%PremiumJul 19, 2024Expiry Date0.16Intrinsic Value100Multiplier7DDays to Expiry1.19Extrinsic Value100Contract SizeAmericanOptions Type-0.5034Delta0.1332Gamma47.87Leverage Ratio-0.0738Theta-0.0061Rho-24.10Eff Leverage0.0352Vega
Intraday
- 5D
- Daily
News
Expert Ratings For RadNet
4 analysts have shared their evaluations of RadNet (NASDAQ:RDNT) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings,
RadNet Is Maintained at Buy by Jefferies
RadNet Is Maintained at Buy by
Jefferies Maintains RadNet(RDNT.US) With Buy Rating, Raises Target Price to $75
Jefferies analyst Brian Tanquilut maintains $RadNet(RDNT.US)$ with a buy rating, and adjusts the target price from $61 to $75.According to TipRanks data, the analyst has a success rate of 48.8% and
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Centene (CNC) and Radnet (RDNT)
Express News | RadNet Inc : Jefferies Raises Target Price to $75 From $61
RadNet Is Maintained at Equal-Weight by Barclays
RadNet Is Maintained at Equal-Weight by
Comments
$RadNet(RDNT.US$ Significant insider selling in June. Cant blame them.
The combination of a rather low ROE and significant use of debt is not particularly appealing. Investors should consider how a company might perform if it was unable to borrow so easily, as credit markets do change over time.
2
RadNet's high P/S ratio may be due to expectations of accelerated revenue performance. However, with revenue growth forecasted to align with the industry, the elevated P/S ratio may not be sustainable. Maintaining the current share price could be challenging unless RadNet outperforms the industry in the short term.
RadNet's CEO sees the Houston acquisition as a strong platform for growth, with potential for more acquisitions, de novo build-outs, health system partnerships, and expansion of AI and digital health solutions. The Houston market aligns with other successful RadNet core geographies.
1
Market focus is on RadNet's top line growth due to its small profit. The share price growth reflects this progress. The recent improvement in total shareholder return could indicate business improvement over time.
Read more